AU Patent

AU2020281641B2 — Ophthalmic composition for the treatment of ocular allergy

Assigned to Novaliq GmbH · Expires 2025-09-11 · 1y expired

What this patent protects

The invention provides ophthalmic composition comprising cyclosporine and a semifluorinated alkane for use in the treatment of ocular allergy and any symptoms associated thereto.

USPTO Abstract

The invention provides ophthalmic composition comprising cyclosporine and a semifluorinated alkane for use in the treatment of ocular allergy and any symptoms associated thereto.

Drugs covered by this patent

Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)

Patent Metadata

Patent number: AU2020281641B2
Jurisdiction: AU
Classification: —
Expires: 2025-09-11
Drug substance claim: No
Drug product claim: No
Assignee: Novaliq GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.